ZW-98

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ZW-98
• 英文别名: 5-(2-phenyl-1-ethynyl)-3-(1-methyl-2(S)-pyrrolidinylmethoxy)pyridine；5-(2-phenylethynyl)-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine；3-((S)-1-methylpyrrolidin-2-ylmethoxy)-5-phenylethynylpyridine；3-((S)-1-Methyl-pyrrolidin-2-ylmethoxy)-5-phenylethynyl-pyridine；3-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5-(2-phenylethynyl)pyridine
• 化学式: C₁₉H₂₀N₂O
• 分子量: 292.381
• InChiKey: FVKMUNYZQFUOQQ-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基-L-脯氨醇 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydride 作用下， 生成 ZW-98
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543

  摘要：

  In an effort to probe the steric influence of C5 substitution of the pyridine ring on CNS binding affinity, analogues of 1 substituted with a bulky moiety--such as phenyl, substituted phenyl, or heteroaryl--were synthesized and tested in vitro for neuronal nicotinic acetylcholine receptor binding affinity. The substituted analogues exhibited K-i values ranging from 0.055 to 0.69 nM compared to a K-i value of 0.15 nM for compound 1. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors led to identify several agonists and antagonists. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00030-0

文献信息

• [EN] PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF<br/>[FR] LIGANDS NICOTINIQUES SUBSTITUÉS PAR UN PHÉNYLE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV GEORGETOWN

  公开号：WO2013071067A1

  公开（公告）日：2013-05-16

  Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.

  本发明涉及化合物及其使用方法，用于治疗以下疾病中的一种或多种：成瘾、疼痛、肥胖、精神分裂症、癫痫、躁狂和躁郁症、焦虑、阿尔茨海默病、学习缺陷、认知缺陷、注意力缺陷、记忆丧失、Lewy体痴呆、注意力缺陷多动障碍（ADHD）、帕金森病、亨廷顿病、抽动症、肌萎缩性侧索硬化、炎症、中风、脊髓损伤、运动障碍、强迫症、化学物质滥用、酗酒、记忆缺失、假性痴呆、甘瑟综合症、偏头痛、贪食症、经前综合症或晚期黄体期综合症、吸烟成瘾、创伤后综合症、社交恐惧症、慢性疲劳综合症、早泄、勃起障碍、厌食症、孤独症、缄默症、拔毛癖、低体温症和睡眠障碍疾病。
• Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them
  申请人：Kozikowski Alan P.

  公开号：US20080132486A1

  公开（公告）日：2008-06-05

  One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

  本发明的一个方面涉及杂环化合物，其是乙酰胆碱受体的配体。本发明的第二个方面涉及使用本发明的化合物来调节哺乳动物的乙酰胆碱受体。本发明还涉及使用本发明的化合物来治疗患有阿尔茨海默病、帕金森病、运动障碍、抽动症、精神分裂症、注意力缺陷障碍、焦虑、疼痛、抑郁症、强迫症、化学物质滥用、酗酒、记忆力障碍、假性痴呆、甘瑟综合征、偏头痛疼痛、贪食症、肥胖症、月经前综合征或黄体酮期后综合征、烟草滥用、创伤后应激障碍、社交恐惧症、慢性疲劳综合征、早泄、勃起障碍、厌食症、睡眠障碍、自闭症、哑症或拔毛癖的哺乳动物。
• Synthesis and structure–activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543
  作者：Nan-Horng Lin、Yihong Li、Yun He、Mark W Holladay、Theresa Kuntzweiler、David J Anderson、Jeffrey E Campbell、Stephen P Arneric

  DOI：10.1016/s0960-894x(01)00030-0

  日期：2001.3

  In an effort to probe the steric influence of C5 substitution of the pyridine ring on CNS binding affinity, analogues of 1 substituted with a bulky moiety--such as phenyl, substituted phenyl, or heteroaryl--were synthesized and tested in vitro for neuronal nicotinic acetylcholine receptor binding affinity. The substituted analogues exhibited K-i values ranging from 0.055 to 0.69 nM compared to a K-i value of 0.15 nM for compound 1. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors led to identify several agonists and antagonists. (C) 2001 Elsevier Science Ltd. All rights reserved.
• 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION
  申请人：Abbott Laboratories

  公开号：EP0934308B1

  公开（公告）日：2004-08-11
• NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM
  申请人：Xiao Yingxian

  公开号：US20100129291A1

  公开（公告）日：2010-05-27

  The present invention discloses nicotinic desensitizers and methods of selecting, testing, and using them. The present invention provides methods for selecting nicotinic desensitizers from one or more compounds by using receptor, cell, and tissue models; and methods for testing one or more nicotinic desensitizers for their therapeutic utility by using animal models. The present invention also provides compounds of formula (I) and (II) as nicotinic desensitizers. Nicotinic desensitizers of the present invention are useful for the treatment of a wide range of conditions, diseases, and disorders.